Storys aus Zug, Switzerlandz

Filtern
  • 19.12.2014 – 09:01

    AmVac AG

    New possibilities in the fight against pancreatic cancer

    Zug, Switzerland (ots) - Licence extension in the contract between AmVac and the Helmholtz Centre for the adjuvant Malp-2 offers sustainable potential for patients, attending physicians and for pharmaceutical and medical research. Milestone thanks to licence extension The licence for Malp-2 was successfully extended in November 2014. The adjuvant can now be used for the first time for all preventive and therapeutic ...